Category 1 vs. Category 2: The Two 503A Bulks Lists Explained
August 3, 2026
Two lists, two meanings
Public discussion of compounding often collapses “the FDA list” into one idea. In the 503A framework, that creates confusion. At minimum, readers should keep two concepts separate:
### Category 1 — Bulk Drug Substances List
This is the affirmative list of bulk substances FDA has determined may be used in 503A compounding when other statutory conditions are met. Formal addition generally requires rulemaking (proposed rule → comments → final rule).
### Category 2 — Significant safety risk / do-not-compound posture
This is the posture associated with substances FDA has identified as presenting significant safety risks for compounding. Being discussed in connection with Category 2 is not the same regulatory event as being placed on Category 1.
The interim trap
A common misread after advisory meetings is: “the committee recommended yes, so compounding is now authorized.” Primary and secondary regulatory explainers converge on the opposite point:
- Removal from a safety-risk posture (where that occurs) is **not** automatic Category 1 listing
- A favorable PCAC vote is **not** Category 1 listing
- Until FDA affirmatively places a substance on Category 1 (or otherwise establishes a clear enforcement policy tied to that determination), traditional 503A compounding of that bulk remains outside the formal listed pathway
Why the distinction matters for research buyers
Research-use markets and compounding markets are different channels with different rules. Educational coverage should not blur “advisory recommendation,” “interim enforcement posture,” and “final Category 1 listing.” Treating them as synonyms is how false legal conclusions spread.
Checklist before sharing regulatory news
1. Was this a nomination, a staff briefing, a committee vote, or a final rule?
2. Does the article specify Category 1 vs. Category 2?
3. Does it claim authorization that FDA has not yet published as listing or policy?
If any answer is fuzzy, treat the piece as unfinished process reporting — not as a status change.
*For research use only. Not for human or animal consumption.*
USX Peptides Team
Our research and quality team at USX Peptides.